Related Experiment Video
Updated: Jul 13, 2026

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm
Published on: December 22, 2016
Linezolid-related pancytopenia in organ-transplant patients: report of two cases
1Multiorgan Transplant Unit, University Hospital, CHU Rangueil, Toulouse, France.
Abstract:
Linezolid is a recent oral antibiotic used in drug-resistant Gram-positive cocci infection. We herein report on the first two cases of linezolid-related pancytopenia in organ-transplant patients. Both patients had methicillineresistant Staphylococcus aureus infections. Pancytopenia, i.e. aregenerative anemia, neutropenia and thrombopenia, developed 3 weeks and 5 weeks after initiating linezolid therapy at a conventional dosage (600 mg bid). There were no other confounding causes of pancytopenia, which resolved promptly after withdrawing linezolid. Because of the potential hazards of pancytopenia in immunosuppressed organ-transplant patients, we advocate the cautious use of linezolid for transplant patients.
Insights
Linezolid antibiotic therapy can cause pancytopenia (low blood counts) in organ-transplant patients. This serious side effect resolved after discontinuing linezolid, highlighting the need for caution.
Area of Science:
- Pharmacology
- Hematology
- Infectious Diseases
Background:
- Linezolid is a crucial antibiotic for treating infections caused by drug-resistant Gram-positive bacteria.
- Organ-transplant recipients are often susceptible to severe infections due to immunosuppression.
Observation:
- Two organ-transplant patients developed pancytopenia (anemia, neutropenia, and thrombocytopenia) after initiating linezolid treatment.
- These hematologic abnormalities emerged approximately 3 and 5 weeks into standard-dose linezolid therapy (600 mg twice daily).
Findings:
- No other causes for pancytopenia were identified in these patients.
- Pancytopenia resolved rapidly upon cessation of linezolid, indicating a direct drug-related toxicity.
Implications:
- Linezolid-induced pancytopenia poses a significant risk in immunosuppressed organ-transplant patients.
- Careful monitoring of blood counts is recommended during linezolid therapy in this vulnerable population.
- Judicious use of linezolid is advised for transplant recipients to mitigate potential hematologic complications.
Related Concept Videos
Kidney Transplant I: Introduction
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Kidney Transplant II: Surgical Procedure
Kidney Transplant III: Nursing Management
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...